RGC
HealthcareRegencell Bioscience Holdings Limited · Drug Manufacturers - Specialty & Generic · $13B
What is Regencell Bioscience Holdings Limited?
Regencell Bioscience Holdings is a Hong Kong-based company applying Traditional Chinese Medicine principles to the treatment of neurocognitive disorders, with a focus on ADHD and autism spectrum disorder.
Regencell researches, develops, and seeks to commercialize TCM-based therapies targeting neurocognitive conditions. Rather than conventional pharmaceuticals, the company draws on TCM frameworks to address ADHD and autism spectrum disorder — a niche approach that differentiates it from mainstream drug developers but also limits its established commercial footprint.
Incorporated in 2021 and headquartered in Causeway Bay, Hong Kong.
- TCM-based neurocognitive therapies
- ADHD-focused treatment research
- Autism spectrum disorder treatment development
Is RGC a Good Stock to Buy?
UQS Score rates RGC as Poor overall.
Among the five pillars, Risk stands out as the relative bright spot, suggesting the company carries a comparatively manageable risk profile at this stage.
Quality, Moat, and Growth all register as Weak, reflecting an early-stage business with limited revenue scale and no established competitive advantage. Valuation is rated Elevated, adding further caution.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does RGC pay dividends?
No — Regencell Bioscience Holdings Limited does not currently pay a dividend.
RGC does not currently pay a dividend. As an early-stage bioscience company, available capital is directed toward research and development rather than shareholder distributions — a common posture for pre-revenue or early-revenue healthcare firms.
When does RGC report earnings?
Regencell Bioscience reports earnings on a quarterly cadence, typical for US-listed equities.
Given the company's early-stage profile and Weak Growth pillar rating, recent reporting periods have not demonstrated the revenue momentum or profitability that characterizes more established peers. Progress on research milestones tends to be the more closely watched indicator at this stage.
For the most recent quarter's results, visit Regencell Bioscience's investor relations page directly.
RGC Price History
+66.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
Frequently Asked Questions
What does Regencell Bioscience do?
Regencell Bioscience develops Traditional Chinese Medicine-based therapies aimed at neurocognitive disorders, specifically ADHD and autism spectrum disorder. The company is in an early research and commercialization phase, operating out of Hong Kong.
Does RGC pay dividends?
No, RGC does not pay a dividend. The company is at an early stage and focuses available resources on research and development rather than returning capital to shareholders.
When does RGC report earnings?
Regencell Bioscience follows a quarterly reporting cadence. For the exact schedule and most recent results, check the company's official investor relations page.
Is RGC a good stock to buy?
UQS Score rates RGC as Poor, with Weak readings across Quality, Moat, and Growth, and an Elevated Valuation. Risk is the only pillar showing relative strength. Investors should weigh these factors carefully before making a decision.
Is RGC overvalued?
The UQS Valuation pillar for RGC is rated Elevated, suggesting the current market price is not well supported by the company's underlying fundamentals at this stage of development.
Is RGC a long-term quality investment?
As a long-term quality indicator, UQS Score rates RGC as Poor. The Weak Moat and Quality pillars indicate the company has not yet built the durable competitive advantages or financial foundation typically associated with long-term compounders.
What sector does RGC belong to?
RGC operates in the Healthcare sector, specifically within the niche of TCM-based bioscience targeting neurocognitive conditions. This positions it differently from conventional pharmaceutical or biotech peers.
What is RGC's market cap bracket?
Despite its early-stage profile and limited commercial history, RGC is classified as a large-cap company by market capitalization — a notable divergence from its underlying fundamental ratings.
Unlock Full RGC Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown for RGC
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare RGC against sector peers on quality and valuation
- ✓Get the full analyst view available to Pro members
Pro Analysis
RGC — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | 9.4 | 0.0 | 3.0 | 0.0 | 57.5 | 0.0 | -1.9 |
| May 12, 2026 | 11.3 | 0.0 | 3.0 | 0.0 | 70.3 | 0.0 | +3.6 |
| May 9, 2026 | 7.7 | 0.0 | 3.0 | 0.0 | 46.2 | 0.0 | -3.6 |
| Apr 2, 2026 | 11.3 | 0.0 | 3.0 | 0.0 | 70.3 | 0.0 | — |
RGC — Pillar Breakdown
Quality
— 0.0/100 (25%)Regencell Bioscience Holdings Limited currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Regencell Bioscience Holdings Limited faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Analyst consensus for future revenue growth.
Risk
— 57.5/100 (15%)Regencell Bioscience Holdings Limited maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Regencell Bioscience Holdings Limited appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 3/100 (25%)Regencell Bioscience Holdings Limited operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RGC.
Score Composition
Financial Data
More Stock Analysis
How is the RGC UQS Score Calculated?
The UQS (Unified Quality Score) for Regencell Bioscience Holdings Limited is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Regencell Bioscience Holdings Limited's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Regencell Bioscience Holdings Limited is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.